We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ: NTUS), in connection with the proposed acquisition of the Company by an affiliate of ArchiMed.  Under the terms of the merger agreement, the Company’s shareholders will receive $33.50 in cash for each share of Natus common stock owned.  The transaction is valued at $1.2 billion.

Weiss Law is investigating whether (i) Natus’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $33.50 per-share merger consideration adequately compensates Natus’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.